Mount Sinai researchers published a study that could improve neuroscientists’ understanding of the progression of Alzheimer’s and other forms of cognitive decline. It proved that white matter may be a more important region to look at than was previously thought.
Biogen plans to launch a virtual study with Apple this year to identify early signs of mild cognitive impairment. The study is expected to launch in the second half of 2021.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
From a new treatment for sickle cell disease to supersized acquisitions, some of the biggest stories in 2019 set the stage for the new year.
Company plans to bring three drugs for FTD and Alzheimer's into clinic early next year.
Gates will invest $50 million in the Dementia Discovery Fund. This will be followed by another $50 million investment in startups working on Alzheimer's research.
Here's a look at some of the most popular stories from this past week in healthcare.
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
Robert Califf, a deputy commissioner at the FDA, says that in order to accelerate medical treatment options for diseases like Alzheimer's, we must improve our basic understanding of disease processes.
For diseases like Parkinson’s and Alzheimer’s, it seems like symptoms are a function of what’s going on deep down inside of whoever is afflicted – a reflection of something happening at the core. But what if detection could be right in front of our faces, just on the surface of a patient’s skin? Dr. Ildefonso […]
The list of 2015 Oscar nominees has already been criticized a lot. Too white, too male and no nominations for the Lego Movie or Selma. They also ignored “Cake” that stars Jennifer Aniston. She is a woman who lives in chronic pain. Apparently she is also a jerk, as she gets kicked out of a […]
We’re in the era of immunotherapy, of monoclonal antibodies and anti-inflammation drugs and personalized medicine. Insert buzzword. Startups in these spaces tend to attract a sizable swath of cash, particularly if they’re in the lucrative cancer diagnostics or therapeutics space – but what else is out there? Lots. Here are some startups that pique the interest: […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
There’s a serious dearth of psychiatric drugs under development, but Janssen is taking a gander at speeding up innovation on that front. The project’s called Neuroscience Catalyst. Over the course of three years, Janssen and Johnson & Johnson Innovation plan to set up 10 research projects that examine mood disorders, Alzheimer’s disease and other neurological conditions. Working […]
An entrepreneur has started an Indiegogo campaign to support a digital health platform that inserts family pictures into gaming and art therapy activities. The aim is to help Alzheimer's disease patients and others battling neurological conditions as they struggle with memory loss. MemVu wants to add apps to the program to make it more flexible to use.
Confused on the Donald Sterling trial? @writerkev joins the show to discuss. 6ET @FOXSports1 http://t.co/XeiefpMPzI pic.twitter.com/M2t6eQpPQ1 — America’s Pregame (@AmericasPregame) July 21, 2014 An interesting HIPAA-related angle in the Donald Sterling trial — the, ah, outspoken longtime Los Angeles Clippers owner can’t use medical privacy laws to strike doctors’ testimony that he has Alzheimer’s disease, […]
A $1 million seed fund is being launched at the University of Wisconsin, with an initial aim of nudging its Alzheimer’s disease research a little closer to the bedside. Half the seed funding comes from donations to the Wisconsin Technology Innovation Institute (Wi2), a UW-affiliated nonprofit; this is matched by a $500,000 contribution from the […]